Use of Two Epithelium-Specific Monoclonal Antibodies for Diagnosis of Malignancy in Serous Effusions

“…This apical and cytoplasmic staining pattern of human mammary epithelium has also been described using antibodies produced against milk fat globule membrane (2,3) and breast carcinoma cells (4). MAb DF3, however, can be distinguished from other MAbs generated against milk fat globule membrane and breast tumors on the basis of the molecular weight of the cross-reactive antigen (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.

Hayes¹,

Shinmoto²,

Ohno³

et al. 1985

J. Clin. Invest.

192

View full text Add to dashboard Cite

The murine monoclonal antibody (MAb), designated DF3, reacts with a 300,000-mol wt mammary epithelial antigen. A sequential double-determinant radioimmunoassay (RIA) has been developed to monitor circulating DF3 antigen. Using this assay, we have demonstrated that 33 of 36 normal women had plasma RIA antigen levels < 150 U/mi. In contrast, 33 of 43 patients (76%) with metastatic breast cancer had RIA DF3 antigen levels _ 150 U/ml. The difference between these two groups was statistically significant (P < 0.001). Similar results have been obtained with a double-determinant enzyme-linked immunoassay (EIA). Only 6 of 111 age-matched normal subjects had EIA DF3 antigens levels _ 30 U/ml, while 42 of 58 patients (72%) with breast cancer had levels equal to or above this value. Thus, similar patterns of specificity are obtained with the EIA or RIA. The elevation of circulating DF3 antigen levels in breast cancer patients has been confirmed by transfer blot assays. MAb DF3 reactivity occurred predominantly with circulating antigens of three different molecular weights ranging from 300,000 to -400,000 mol wt. We also demonstrate that patients with both primary and metastatic breast cancer who were free of detectable disease at the time of sampling have DF3 antigen levels that are similar to those obtained from normal subjects. While patients with hepatoma (27%) and ovarian carcinoma (47%) also had elevated circulating DF3 antigen levels, the results suggest that DF3 antigen levels may be useful in distinguishing breast cancer patients from those with esophageal, gastric, colorectal, pancreatic, and lung carcinomas. Furthermore, the results of the RIA, EIA, and transblot analyses demonstrate that the measurement of circulating DF3 antigen levels provides a new and potentially useful marker to follow the clinical course of patients with metastatic breast cancer.

show abstract

“…Antisera to EMA have been used for the detection of bone marrow and lymph node metastases from breast carcinoma (Heyderman et al, 1979;Sloane et al, 1980a,b;Gugliotta et al, 1981;Dearnaley et al, 1981Dearnaley et al, , 1983Redding et al, 1983), and for identification of malignant cells in serous effusions Epenetos et al, 1982).…”

mentioning

confidence: 99%

A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2

Heyderman¹,

Strudley²,

Powell³

et al. 1985

Br J Cancer

View full text Add to dashboard Cite

Summary Two polyclonal rabbit antibodies to epithelial membrane antogen (EMA), two mouse monoclonal antibodies (E29 and HMFG-2), and a "cocktail" of these two monoclonals have been compared using an indirect immunoperoxidase technique. Sections from 25 tissues (17 malignant and 8 benign), were examined. The distribution of staining with each of these reagents was similar, but the polyclonal antibodies produced stronger staining in colorectal carcinomas and lactating breast, whereas staining with the monoclonal antibodies was stronger in non-neoplastic pleural mesothelium and in pulmonary alveolar cells. When the two monoclonals were mixed there was no increase in staining intensity. E29 gave a "cleaner" result than HMFG-2, with better discrimination between cells and stroma, and is highly suitable for routine diagnostic histopathology.

show abstract

Use of Two Epithelium-Specific Monoclonal Antibodies for Diagnosis of Malignancy in Serous Effusions

Cited by 122 publications

References 12 publications

Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance

Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance

Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.

A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2

Contact Info

Product

Resources

About